EORTC partners with Pierre Fabre to support patients with stage 2 melanoma
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma. The partnership includes the planning, design and execution of a large Phase 3 study investigating the use of BRAF and MEK targeted therapies to reduce the risk of relapse in this patient population, currently under approval with authorities.
Sadly, still today too many patients with Stage 2 melanoma have their cancer come back, even after their tumor is removed. Further understanding how effective treatments can have an impact on recurrence is essential. We are pleased to collaborate with Pierre Fabre who bring strong heritage and expertise in this therapeutic area, to make a true difference to people living with Stage 2 melanoma.
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for
europapress.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europapress.es Daily Mail and Mail on Sunday newspapers.